The Continuing Education (CE) courses provide excellent lectures
to participants at Annual Meetings and SOT makes some of the course presentations
available to a wider audience. Outstanding speakers have been identified based upon course evaluations, and these selected
speakers have agreed to participate in the SOT CE Speaker Bureau. Any
Regional Chapter may request a presenter from the list below for chapter
meetings, and SOT will provide funding to cover the speaker's costs through
Funding for
Regional Chapter Activities and Speakers. These funds are limited and evaluated on a quarterly basis, so it is important to put your request in early. Please contact Marcia Lawson for more information and to submit your request.
Steven A. Belinsky
Lovelace Respiratory Research Institute
Albequerque, NM |
Epigenome Profiling: Mapping Epigenetic Alterations in Health and Disease
(2010, Salt Lake City) |
Dr. Belinsky has worked in the field of tobacco carcinogenesis for >20 years and is internationally recognized for his work in lung cancer and translational studies for early detection of lung cancer. His research is currently focused on controlling lung cancer through the identification of gene targets and pathways that are disrupted during the development of this disease. |
Gary J. Chellman, Ph.D.,DABT
Charles River Preclinical Services
Reno, NV |
Post-natal and Juvenile Toxicity Studies in Non-Human Primates
(2011, Washington, D.C.) |
Nonhuman primate developmental and reproductive toxicology. Contemporary study designs and data interpretation to evaluate embryo-fetal development, pre-postnatal development, male and female reproduction, and juvenile toxicity. |
James A. Dykens, Ph.D.
Pfizer Global Research & Development,
Sandwich, UK |
Mitochondrial Function and Dysfunction in Disease and Drug-Induced Toxicity
(2010, Salt Lake City) |
Mitochondrial physiology; cellular and organismal bioenergetics; off-target drug toxicity; idiosyncratic drug reaction; improvement of pre-clinical in vitro safety screening. |
Marc E. Gillespie, Ph.D.
St. John’s University
Jamaica, NY |
Reactome Knowledgebase
(2011, Washington, D.C.) |
Specialties in bioinformatics, biocuration, proteomics, and toxicology. Leads a toxicogenomic research group and is an editor for Reactome, an international project focused on core human biological pathways. Tutorials, workshops, and lectures covering pathway analysis tools, biological pathway identification within and between species, and tools for bulk queries across datasets |
Susan G. Emeigh Hart, VMD, Ph.D., DACVP, DABT, ERT
Auxilium Pharmaceuticals, Inc.
Malvern, PA |
The Kidney: Anatomic and Physiologic Features of Mechanistic Relevance
(2010, Salt Lake City) |
Renal and ocular anatomy and physiology (normal and pathologic), renal and ocular toxicology, anatomic and clinical pathology of laboratory animals, extracellular matrix biology and pathophysiology, drug development (small molecule and biologics, pre-IND to NDA/BLA) |
Shawn M. Heidel, DVM, Ph.D.
Eli Lilly & Company
Indianapolis, IN |
Principles for Development of Proteins
(2010, Salt Lake City) |
Safety assessment of biopharmaceuticals, comparability testing, biosimilars, and regulatory toxicology. |
Christopher Horvath, DVM, DACVP
Taligen Therapeutics,
Cambridge, MA |
Cytokine Storms: It’s Not Nice to Fool With Mother Nature
(2010, Salt Lake City) |
Translational (preclinical to clinical) development of biologics, FIH dose selection and justification, immunogenicity effects, comparative immunopathology, establishing NOAELs |
Randy L. Jirtle, Ph.D.
Duke University Medical Center,
Durham, NC |
Environmental Epigenomics and Disease Susceptibility
(2010, Salt Lake City) |
Role of epigenetics and genomic imprinting in human health and toxicological risk assessment. |
Daniel M. Lapadula, Ph.D., DABT
Novartis Pharmaceuticals Corporation,
East Hanover, NJ |
Preclinical Development of Oncology Therapeutics: An Industry Perspective
(2010, Salt Lake City) |
Accelerating drug development of anticancer drugs and impact of new regulatory guidance. |
John C. Lipscomb, Ph.D., DABT
U.S. EPA
Cincinnati, OH |
Toxicokinetics in Risk Assessment
(2011, Washington, D.C.) |
Quantitative approaches to human health risk assessment, including extrapolation of findings related to response (toxicodynamics) and disposition (toxicokinetics); application of physiologically-based pharmacokinetic modeling in risk assessment; mixtures toxicology and risk assessment approaches; use of mode of action in health risk assessment. |
Carolyn J. Mattingly, D.Phil.
Mount Desert Island Biological Laboratory
Salisbury Cove, ME |
Comparative Toxicogenomics Database (CTD)
(2011, Washington, D.C.) |
Toxicgenomics; data resources to develop hypotheses about the effects of environmental chemicals on human health; zebrafish as a comparative model for developmental and mechanistic toxicology. |
Kevin T. Morgan, Ph.D.
Safoni-Aventis
Research Triangle Park, NC |
From the Land of Classical Mammalian Toxicology and Pathology to the Land of In Vitro, Molecular, Genomics, and Other Tools
(2010, Salt Lake City) |
- The meaning of life.
- Biology in general, especially with respect to dynamics as it relates to understanding 'omics' data.
- Normal physiology with special reference to intermediary metabolism and bioenergetics.
- Mechanisms of disease.
- The application of mathematical modeling to Biology.
|
Kent E. Pinkerton, Ph.D.
University of California
Davis, CA |
Comparative Anatomy of Mammalian Respiratory Systems
(2010, Salt Lake City) |
The health impacts of inhaled gases and particles on the respiratory system. The effects of environmental tobacco smoke and airborne particulates on perinatal development of the respiratory,immune and neural systems. Adverse and beneficial effects of inhaled engineered nanomaterials. |
Paul S. Price
The Dow Chemical Company
Midland, MI |
New Tools—How Do They Affect the Bottom Line?
(2010, Salt Lake City) |
Characterizing risks from mixtures; Understanding how advances in toxicology can help improve risk assessments; and Using probabilistic techniques to improve risk assessment.
|
R. Dustan Sarazan, DVM, Ph.D.
Data Sciences International
St. Paul, MN |
Integrated Assessment of Cardiovascular Functional Liabilities: In Vitro Animal Models
(2011, Washington, D.C.) |
Cardiovascular physiology and pharmacology with an emphasis on hemodynamics and cardiac function. Cardiovascular safety pharmacology. Functional CV safety assessment in repeat dose toxicology studies. Biomedical instrumentation and the study of systems physiology. |
Jane Ellen Simmons, Ph.D., DABT
U.S. EPA
Research Triangle Park, NC |
Basic Principles of Additivity Underlying Methods, Designs, and Techniques for Evaluation of Mixtures
(2011, Washington, D.C.) |
|
Donald G. Stump, Ph.D., DABT
WIL Research Laboratories LLC
Ashland, OH |
Post-natal and Juvenile Toxicity Studies: Basic Study Designs and Practical Approaches
(2011, Washington, D.C.) |
Developmental, reproductive, juvenile and neurotoxicity assessment for pharmaceuticals, biologics and agricultural chemicals. |
Jeffrey S. Tepper, Ph.D., DABT
Tepper Nonclinical Consulting,
San Carlos, CA |
Interpretation and Limitations in the Assessment of Lung Function in Laboratory Mammals
(2010, Salt Lake City) |
Biopharmaceutical pharmacology and regulatory toxicology. Particular expertise in inhalation toxicology and animal models of respiratory and immunological disease. |
Mark Vezina
Charles River Laboratories,
Montreal, QC, Canada |
Comparative Ocular Anatomy and Physiology in Laboratory Animals
(2010, Salt Lake City) |
Ocular safety evaluations, ocular tissue distribution, retinal electrophysiology, neuroprotection and animal models of ocular disease |
Yvonne Will, Ph.D.
Pfizer Global Research & Development
Groton, CT |
In Vitro Approaches to Assess Mitochondrial Toxicity and Mitochondria-Mediated Drug Toxicity: Advantages and Limitations
(2010, Salt Lake City) |
Mitochondrial toxicity, HTS applicable safety screens, liver injury, cardio toxicity, cell based assays |
